BofA upgraded Danaher (DHR) to Buy from Neutral with an unchanged price target of $290. The recent pullback has created a more attractive entry point, says the firm, which believes shares may outperform in 2025 as bioprocess recovery takes center stage amid “more realistic” buyside expectations.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher upgraded to Buy from Neutral at BofA
- Danaher put volume heavy and directionally bearish
- Third Point exits Alphabet, cuts stakes in Microsoft, Amazon, Meta, Apple
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Danaher upgraded to Outperform from Peer Perform at Wolfe Research